Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9UP52
UPID:
TFR2_HUMAN
Alternative names:
-
Alternative UPACC:
Q9UP52; A6NGM7; O75422; Q1HE13; Q9HA99; Q9NX67
Background:
Transferrin receptor protein 2 plays a crucial role in iron homeostasis, mediating the cellular uptake of transferrin-bound iron. Its involvement in iron metabolism, hepatocyte function, and erythrocyte differentiation highlights its importance in maintaining iron levels within physiological ranges.
Therapeutic significance:
Given its pivotal role in iron metabolism and association with Hemochromatosis 3, a disorder characterized by iron overload, Transferrin receptor protein 2 presents a promising target for therapeutic intervention. Understanding its function could lead to novel treatments for diseases caused by iron dysregulation.